Name
|
Antimicrobial coverage & uses
|
Mupirocin
|
- inhibits bacterial protein synthesis
-
targets primarily Gram-positive organisms; S
aureus (most MRSA) &
most streptococci.
- Many Gram-negative pathogens, including
enteric bacilli and other enterococci = not affected
- common use:
- localized impetigo due to S
aureus & Streptococcus pyogenes
- eradication of nasal
colonization with S. aureus
|
Neomycin
|
- interferes with bacterial protein synthesis.
- common use:
- treat infections by aerobic
Gram-positive & Gram-negative bacilli (S aureus[Gram-positive] and
E coli)
- prevent infection in superficial
abrasions, cuts, and burns.
|
Fusidic acid
|
- active against: Staphylococcus aureus, streptococci (in topical concentrations),
corynebacteria, & clostridia
- treat primary skin infections: impetigo
contagiosa & erythrasma
- treat secondary skin infections: infected
wounds & burns
|
*Topical mupirocin should be
reserved for treating patients with localised mild skin infections (impetigo or
infected eczema), that are resistant to fusidic acid and have sensitivity to
mupirocin.
** Blue book indication for
Mupirocin 2% Ointment: For MRSA infections only
References
1. http://www.medscape.org/viewarticle/457542_6
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.